Sylvia E. Rosas

Diabetes Care · 2022

A researcher in the Science corpus: 3 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from Sylvia E. Rosas's perspective

Ordered by how strongly the researchers Sylvia E. Rosas trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. (The Lancet)
  2. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. (New England Journal of Medicine)
  3. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. (Journal of Clinical Epidemiology)
  4. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. (The Lancet Diabetes and Endocrinology)
  5. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. (The Lancet)
  6. Social Determinants of Health and Diabetes: A Scientific Review (Diabetes Care)
  7. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association (Diabetes Care)
  8. Tirzepatide Once Weekly for the Treatment of Obesity. (New England Journal of Medicine)
  9. Exercise/Physical Activity in Individuals with Type 2 Diabetes: A Consensus Statement from the American College of Sports Medicine (Medicine & Science in Sports & Exercise)
  10. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra‐Virgin Olive Oil or Nuts (New England Journal of Medicine)

Their papers